* estimated life expectancy under three months due to severe comorbidity * asat/alat-ratio over five-fold upper limit * acute myocardial infarction or unstable angina pectoris * breast feeding or pregnancy * any reason why, in the opinion of the investigators, the patient should not participate * patient participates in a potentially confounding drug or device trial during the course of the study * already receiving any of the study drugs * severe renal failure (egfr \< 30 ml/min)

* estimated life expectancy under three months due to severe comorbidity * asat/alat-ratio over five-fold upper limit * acute myocardial infarction or unstable angina pectoris * breast feeding or pregnancy * any reason why, in the opinion of the investigators, the patient should not participate * patient participates in a potentially confounding drug or device trial during the course of the study * already receiving any of the study drugs * severe renal failure (egfr \< 30 ml/min)

estimated life expectancy under three months due to severe comorbidity asat/alat-ratio over five-fold upper limit acute myocardial infarction or unstable angina pectoris breast feeding or pregnancy any reason why, in the opinion of the investigators, the patient should not participate patient participates in a potentially confounding drug or device trial during the course of the study already receiving any of the study drugs severe renal failure (egfr < 30 ml/min)

estimated life expectancy under three months due to severe comorbidity asat/alat-ratio over five-fold upper limit acute myocardial infarction or unstable angina pectoris breast feeding or pregnancy any reason why, in the opinion of the investigators, the patient should not participate patient participates in a potentially confounding drug or device trial during the course of the study already receiving any of the study drugs severe renal failure (egfr < 30 ml/min)